Knightsbridge Asset Management’s Harvard Bioscience HBIO Stock Holding History

Knightsbridge Asset Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-27,515	Closed	-$831K	–	29
2016 Q1	$831K	Hold	27,515	–	–	0.64%	25
2015 Q4	$955K	Hold	27,515	–	–	0.68%	24
2015 Q3	$1.04M	Sell	27,515 -340	-1%	-$15.8K	0.73%	23
2015 Q2	$1.59M	Sell	27,855 -5,580	-17%	-$318K	0.82%	25
2015 Q1	$1.95M	Buy	33,435 +15	+0%	+$806	0.95%	21
2014 Q4	$1.9M	Hold	33,420	–	–	0.61%	25
2014 Q3	$1.37M	Sell	33,420 -130	-0.4%	-$5.98K	0.41%	29
2014 Q2	$1.53M	Buy	33,550 +7,218	+27%	+$303K	0.4%	30
2014 Q1	$1.25M	Buy	26,332 +20,438	+347%	+$930K	0.35%	30
2013 Q4	$277K	Buy	+5,894	New	+$257K	0.07%	40

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Knightsbridge Asset Management's HBIO Position: Q2 2016 in Review

Knightsbridge Asset Management sold out of Harvard Bioscience (HBIO) in Q2 2016, closing a stake of 27,515 shares — an estimated $831K sold.

Knightsbridge Asset Management first reported a position in HBIO in Q4 2013 and held it in 10 quarters. The position peaked at $1.95M in Q1 2015. 81 funds tracked by Wall St. Rank hold HBIO as of Q2 2016.

Knightsbridge Asset Management reported no remaining Harvard Bioscience position as of Q2 2016 after selling out during the quarter.
Knightsbridge Asset Management sold 27,515 Harvard Bioscience shares in Q2 2016, an estimated $831K.
Knightsbridge Asset Management first reported a position in Harvard Bioscience in Q4 2013 and held it in 10 quarters.
Knightsbridge Asset Management's Harvard Bioscience position peaked at $1.95M in Q1 2015.
81 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2016.

Based on Knightsbridge Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.